Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing
HHS Secretary Azar explains why companies have not voluntarily lowered prices as yet, despite President Trump’s recent comments. He also discussed using regulations to prohibit rebates.
You may also be interested in...
Letter to seven pharmacy benefit managers seeks insight into pros and cons of practices, suggesting that policymakers understand PBMs bring value in lowering costs but that some activities are counterproductive.
Letters to several pharmacy benefit managers and wholesalers request information on whether middlemen have discouraged decrease in list prices.
Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.